Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
243.58
+5.93 (2.50%)
At close: May 13, 2026, 4:00 PM EDT
243.36
-0.22 (-0.09%)
After-hours: May 13, 2026, 5:37 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$839,568
Profits / Employee
$480,917
Market Cap
15.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 4,700 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
ASND News
- 2 days ago - Ascendis Pharma price target raised to $345 from $342 at Barclays - TheFly
- 5 days ago - Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo - TheFly
- 6 days ago - Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15) - TheFly
- 6 days ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 6 days ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 7 days ago - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - GlobeNewsWire
- 13 days ago - Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - GlobeNewsWire
- 22 days ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire